Leprosy Mailing List – July 11, 2022
Ref.: (LML) Safer and newer antimicrobial drugs for leprosy needed
From: Diana Lockwood, London, UK
Dear Pieter,
Safer and newer antimicrobial drugs for leprosy– time to test monthly ROM in an adequately powered randomised trial?
Diana N. J. Lockwood, Gerson O. Penna, Saba Lambert, Vivek Vasudev Pai & Stephen L. Walker
Lepr Rev (2022) 93, 96–101
We are posting the link and attaching a pdf to an editorial we have written about the need for a large randomised controlled trail of monthly Rifampicin, Ofloxacin and minocycline in comparison with the current WHO multidrug regimen of Monthly Rifampicin, daily Clofazimine and daily Dapsone. The proposed regimen would reduce mortality and morbidity associated with the adverse effects of WHO MDT. Th editorial has been written by leprologists across the world and is an important step to improve treatment. We hope that the leprosy community and organisations will take up the challenge.
DOI: 10.47276/lr.93.2.96
Diana Lockwood
Steve Walker
BW
Diana NJ Lockwood
Emeritus professor of Tropical Medicine
London School of Hygiene & Tropical Medicine
Keppel St
London WC1E 7HT
Visit my blog http://dnjtravels.blogspot.co.uk/
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
--You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/9e378fa5-c12c-4328-8ef5-9854177f86c7n%40googlegroups.com.
No comments:
Post a Comment